Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

LGVN
Longeveron Inc. Common Stock
stock NASDAQ

At Close
Jun 18, 2025 3:59:53 PM EDT
1.22USD-0.410%(0.00)65,341
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jun 18, 2025 8:00:30 AM EDT
1.31USD+7.377%(+0.09)126
After-hours
Jun 16, 2025 4:05:30 PM EDT
1.30USD0.000%(0.00)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
09:16AM EST  LGVN: Using Cellular Technology to Ease Major Medical Issues   Benzinga
Jan 27, 2022
05:01AM EST  41 Biggest Movers From Yesterday   Benzinga
Jan 26, 2022
02:04PM EST  Watching Longeveron Shares; Zacks Small-Cap Research Sets $20 Valuation   Benzinga
Jan 25, 2022
08:00AM EST  Longeveron to Participate in Phacilitate Advanced Therapies Week   GlobeNewswire Inc
Jan 12, 2022
08:04AM EST  Longeveron Highlights Publication Of Lomecel-B Phase 2b Trial Design In Journal Of Frailty And Aging   Benzinga
08:00AM EST  Longeveron Announces Publication of Lomecel-B Phase 2b Trial   GlobeNewswire Inc
Jan 10, 2022
10:57AM EST  UPDATE: Longeveron Says Expects To Publish Phase 1 Trial Results For Alzheimer's Disease Trial In 2022; Expects To Rapidly Recruit, Enroll Phase 2a Trial   Benzinga
10:49AM EST  Longeveron Issues Slides For Phase 2a Alzheimer's Study   Benzinga
Jan 5, 2022
10:24AM EST  EF Hutton Initiates Coverage On Longeveron with Buy Rating, Announces Price Target of $20   Benzinga
08:00AM EST  Longeveron Announces Initiation of Phase 2a Clinical Trial of   GlobeNewswire Inc
07:31AM EST  Exclusive: Longeveron Kickstarts Its Mid-Stage Alzheimer's Disease Trial   Benzinga
07:30AM EST  EXCLUSIVE: Longeveron Says 'The First Patient Has Consented To Participate In The Trial and Patient Screening Has Begun'   Benzinga
07:30AM EST  EXCLUSIVE: Longeveron Says 'The Phase 2a Trial Is Designed To Measure Brain Anatomy Using MRI, And Include Detailed Assessments Of The Inflammatory And Vascular Systems Thought To Contribute To The Worsening Of Alzhaimer's Disease'   Benzinga
07:30AM EST  EXCLUSIVE: Longeveron Announces Initiation Of Phase 2a Clinical Trial Of Lomecel-B For The Treatment Of Alzheimer's Disease   Benzinga
Jan 4, 2022
08:00AM EST  Longeveron to Participate in the H.C. Wainwright BioConnect 2022   GlobeNewswire Inc
Dec 28, 2021
10:08AM EST  Shares of biotechnology company Longeveron Inc. (LGVN) are up 12 percent on Tuesday's trading after the stock received a rating of 61, as per InvestorsObserver. The stock has been on a upward trend since the past few days.   RTTNews
Dec 15, 2021
04:18PM EST  Longeveron Files Prospectus Relates To Proposed Resale From Time To Time For 2.4M Shares Of Class A Common Stock by Selling Security Holders   Benzinga
Dec 9, 2021
09:50PM EST  Mid-Morning Market Update: Markets Open Lower; US Initial Jobless Claims Drop To 52-Year Low   Benzinga
Dec 6, 2021
08:00AM EST  -- HLHS is a rare congenital heart defect that affects approximately 1,000 babies in the U.S. per year -- Orphan Drug Designation confers certain benefits and may result in seven year market exclusivity upon approval for this indication if all statutory and regulatory requirements are met -- Supplements Rare Pediatric Disease Designation recently granted by FDA   GlobeNewswire Inc
Dec 3, 2021
04:30PM EST  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the closing of its previously announced private placement of common stock and warrants.   GlobeNewswire Inc
02:32PM EST  Mid-Afternoon Market Update: DocuSign Drops Following Weak Revenue Forecast; Longeveron Shares Climb   Benzinga
12:03PM EST  Mid-Day Market Update: Nasdaq Dips Over 400 Points; Marvell Technology Shares Rise Following Upbeat Earnings   Benzinga
10:15AM EST  Mid-Morning Market Update: Markets Open Lower; Big Lots Issues Weak Profit Forecast   Benzinga
05:43AM EST  Longeveron Shares Rise 25% Premarket Following FDA Orphan Drug Designation for Treatment for Hypoplastic Left Heart Syndrome   Benzinga
05:33AM EST  Longeveron on Thursday Was Granted FDA Orphan Drug Designation for Treatment of Hypoplastic Left Heart Syndrome   Benzinga
Dec 1, 2021
05:16AM EST  Longeveron Priced 1.17M Share/Warrant Private Placement @$17.50/Share+Warrant   Benzinga
03:17AM EST  Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement   GlobeNewswire Inc
Nov 30, 2021
05:06PM EST  Longeveron Announces Clinical Collaboration To Study Cell Therapy Aging Treatment In Japan: Why It Matters   Benzinga
05:02PM EST  EXCLUSIVE: Longeveron Reports Co. Entered Into Sponsored Clinical Research Deal With Japan's National Center For Geriatrics And Gerontology, Juntendo University Hospital To Explore Safety, Efficacy Of Lomecel-B In Older Subjects   Benzinga
03:20PM EST  Longeveron Announces Phase 2 Clinical Trial in Japan to Test   GlobeNewswire Inc
Nov 24, 2021
10:23AM EST  Mid-Morning Market Update: Markets Open Lower; Deere Earnings Top Views   Benzinga
Nov 23, 2021
10:33AM EST  Mid-Morning Market Update: Markets Mostly Lower; Best Buy Posts Upbeat Q3 Earnings   Benzinga
Nov 21, 2021
03:05PM EST  The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week   Benzinga
Nov 19, 2021
02:47PM EST  Mid-Afternoon Market Update: Dow Falls 200 Points; Connect Biopharma Shares Tumble   Benzinga
12:07PM EST  Mid-Day Market Update: Crude Oil Down Over 4%; UWM Holdings Shares Surge   Benzinga
10:19AM EST  Mid-Morning Market Update: Markets Mixed; Foot Locker Profit Beats Views   Benzinga
09:10AM EST  Benzinga Pro's Top 5 Stocks To Watch For Friday, Nov. 19, 2021: MRNA, LGVN, GTEC, TUSK, FTNT   Benzinga
05:41AM EST  Longeveron Shares Trading Up 37% Premarket After FDA on Thursday Gave Rare Pediatric Disease Designation to Co's Treatment for Infant Heart Condition   Benzinga
Nov 18, 2021
02:36PM EST  Mid-Afternoon Market Update: Dow Falls 75 Points; Dicerna Pharmaceuticals Shares Spike Higher   Benzinga
12:48PM EST  EXCLUSIVE: Longeveron CEO, Geoff Green & Co-Founder And Chief Scientific Officer, Dr. Josh Hare Now Interviewing On Benzinga's Live Tv   Benzinga
12:35PM EST  Mid-Day Market Update: Macy's Surges After Q3 Results; Amtech Systems Shares Plunge   Benzinga
11:31AM EST  EXCLUSIVE: Longeveron CEO, Geoff Green & Co-Founder And Chief Scientific Officer, Dr. Josh Hare To Appear On Benzinga's Live Tv At 12:45 p.m. ET   Benzinga
10:21AM EST  Mid-Morning Market Update: Markets Down; Kohl's Earnings Top Expectations   Benzinga
08:00AM EST  U.S. Food and Drug Administration Approves   GlobeNewswire Inc
07:30AM EST  EXCLUSIVE: Longeveron Says 'Phase 2 clinical trial underway for Hypoplastic Left heart Syndrome, which affects approximately 1000 babies per year'   Benzinga
07:30AM EST  EXCLUSIVE: Longeveron Reports FDA Granted Rare Pediatric Disease Designation For Co.'s Lomecel-B For Treatment Of Hypoplastic Left Heart Syndrome   Benzinga
Nov 12, 2021
08:00AM EST  Longeveron Inc. Provides Corporate Update and Reports Third   GlobeNewswire Inc
04:26AM EST  Earnings Scheduled For November 12, 2021   Benzinga
Nov 9, 2021
03:06PM EST  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with   GlobeNewswire Inc
Nov 8, 2021
08:30AM EST  Longeveron to Release Third Quarter 2021 Financial Results and   GlobeNewswire Inc
Nov 5, 2021
09:43AM EDT  Longeveron Selects Clinical Research Organization For Phase 2 Alzheimer's Disease Trial   Benzinga
08:30AM EDT  Longeveron Selects Clinical Research Organization for Phase 2   GlobeNewswire Inc
Nov 1, 2021
03:23PM EDT  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with   GlobeNewswire Inc
Oct 20, 2021
08:48AM EDT  Longeveron Announces Activation Of Two New Sites In ELPIS II Trial Of Lomecel-B For Hypoplastic Left Heart Syndrome   RTTNews
08:34AM EDT  Longeveron Announces Activation Of Two New Clinical Sites In ELPIS II Trial Of Lomecel-B For Hypoplastic Left Heart Syndrome   Benzinga
08:30AM EDT  Longeveron Announces Activation of Two New Clinical Sites in ELPIS   GlobeNewswire Inc
Oct 14, 2021
08:04AM EDT  Longeveron To Present At The 2021 Dawson James Securities 6th Annual Small Cap Growth Conference   Benzinga
08:00AM EDT  Longeveron to Present at the 2021 Dawson James Securities 6th   GlobeNewswire Inc
Oct 11, 2021
04:27PM EDT  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with   GlobeNewswire Inc
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 4, 2021
08:43AM EDT  Longeveron Successfully Advancing its Cell-Based Therapy Studies in a Growing Industry Segment   Benzinga
Oct 3, 2021
06:41PM EDT  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with   GlobeNewswire Inc
Sep 29, 2021
01:35PM EDT  Longeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity   Benzinga
10:00AM EDT  -- Lomecel-B significantly decreased biomarker Tie-2 in Aging Frailty subjects at 270 days compared to placebo -- Significant, dose-dependent decrease in Tie-2 at Day 270 -- Oral presentation today at the International Conference for Frailty & Sarcopenia Research   GlobeNewswire Inc
09:40AM EDT  EXCLUSIVE: Longeveron Announces Biomarker Analysis Data From Mid-Stage Study Of Anti-Aging Cell Therapy Candidate   Benzinga
Sep 28, 2021
08:00AM EDT  Longeveron Announces Multiple Presentations at the 11th Annual   GlobeNewswire Inc
Sep 21, 2021
08:00AM EDT  -- Jorge Ruiz, M.D., Associate Director for Clinical Affairs, Geriatric Research at the Miami VA Healthcare System, will present Longeverons Aging Frailty Phase 2b Trial Data   GlobeNewswire Inc
Sep 17, 2021
07:23PM EDT  LONGEVERON ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Longeveron Inc. and Encourages Investors to Contact the Firm   Business Wire
Sep 15, 2021
04:08PM EDT  Heart Hope: Announcing the Encouraging Results of a Cell-Therapy Clinical Study by Longeveron   Benzinga
11:51AM EDT  Gainey McKenna & Egleston Announces A ClassAction   GlobeNewswire Inc
Sep 13, 2021
11:03PM EDT  Pomerantz Law Firm Announces the Filing of a Class Action Against Longeveron   PR Newswire
09:23AM EDT  Longeveron Partners With Kinesiometrics To 'Create and Implement Cutting-Edge Smart Phone App to Measure Physical Responses to Cell Therapy'   Benzinga
09:19AM EDT  Longeveron Partners with Kinesiometrics to Create and Implement   GlobeNewswire Inc
Sep 9, 2021
08:47AM EDT  Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome Patients   Benzinga
08:00AM EDT  --Study meets primary safety endpoint: no major adverse cardiac events (MACE), nor any treatment-related infections during the first month post-treatment.   GlobeNewswire Inc
07:41AM EDT  EXCLUSIVE: Longeveron's Lomecel-B Cell Therapy Meets Primary Safety Endpoint In Phase 1 Rare Congenital Heart Disease Study   Benzinga
07:00AM EDT  EXCLUSIVE: Longeveron Announces Phase 1 Clinical Study Of Lomecel-B Injection In Hypoplastic Left Heart Syndrome Patients Met Primary Safety Endpoint With No Major Adverse Cardiac Events OR Treatment-Related Infections During First Month Post-Treatment   Benzinga
07:00AM EDT  UPDATE: Longeveron Says Secondary Endpoints Suggest Lomecel-B May Improve Long-Term Outcome After Surgery But Should Be 'viewed with caution due to the lack of a control arm for comparison'   Benzinga
Sep 1, 2021
08:00AM EDT  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"),a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that management will present virtually at the H.C. Wainwright 23rd Annual Global Investor Conference.   GlobeNewswire Inc
Aug 24, 2021
08:09AM EDT  The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 13, 2021
07:19AM EDT  Longeveron Q2 EPS $(0.26), Sales $489.00K   Benzinga
07:00AM EDT  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update and reported its financial results for the quarter ended June 30, 2021.   GlobeNewswire Inc
07:00AM EDT  -- Study meets one of the two analyses of primary efficacy endpoint: statistically significant dose-response in six-minute walk test (6MWT) at Day 180   GlobeNewswire Inc
07:00AM EDT  EXCLUSIVE: Longeveron Announces Phase 2b Study Of Lomecel-B For Aging Frailty Meets One Of Two Analysis Of Primary Efficacy Endpoint   Benzinga
04:12AM EDT  Earnings Scheduled For August 13, 2021   Benzinga
Aug 10, 2021
08:30AM EDT  Longeveron to Release Second Quarter 2021 Financial Results and   GlobeNewswire Inc
Jul 29, 2021
03:02PM EDT  Longeveron's Novel Therapy Looks to Tackle COVID-19, Flu-Related ARDS   Benzinga
Jul 25, 2021
10:05AM EDT  The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More   Benzinga
Jul 6, 2021
08:13AM EDT  Longeveron Announces First Patient Treated In Phase 2b Hypoplastic Left Hearth Syndrome Clinical Study   Benzinga
08:00AM EDT  Multicenter, double-blinded, controlled study designed to evaluate safety & efficacy of Lomecel-B intramyocardial injection in infants with HLHS   GlobeNewswire Inc
Jun 30, 2021
08:04AM EDT  Longeveron Announces Two Abstracts Accepted For Presentation At The Gerontological Society Of America 2021 Annual Scientific Meeting   Benzinga
08:00AM EDT  Longeveron Announces Two Abstracts Accepted for Presentation at   GlobeNewswire Inc
Jun 28, 2021
02:00PM EDT  Longeveron, Armed with Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer's Disease, Presenting at AAIC & Headed to Phase 2 Trials   Benzinga
Jun 24, 2021
09:10AM EDT  Longeveron Announces Abstract Highlighting Data from Phase 1 Alzheimer's Disease Trial Accepted for Developing Topics Presentation at the 2021 Annual Alzheimer's Association International Conference   Benzinga
08:01AM EDT  Longvereon Highlights Abstract On Data from Phase 1 Alzheimer's Disease Trial Accepted for Developing Topics Presentation at the 2021 Annual Alzheimer's Association International Conference   Benzinga
08:00AM EDT  Longeveron Announces Abstract Highlighting Data from Phase 1   GlobeNewswire Inc
Jun 15, 2021
08:00AM EDT  Longeveron to Present at Noble Capital Markets Virtual Investor   GlobeNewswire Inc
Jun 14, 2021
01:24PM EDT  Longeveron Shares Tick Higher; Co Publishes Study Titled 'Evaluation of Lomecel-B Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial. (ELPISII)' To ClinicalTrials.Gov Site   Benzinga
Jun 10, 2021
08:00AM EDT  Longeverons Chairman and Chief Science Officer   GlobeNewswire Inc
May 25, 2021
09:00AM EDT  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"),a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Ursula Ungaro will be joining its Board of Directors as of June 1, 2021.   GlobeNewswire Inc
May 18, 2021
09:00AM EDT  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the hiring of Dan Gincel, Ph.D. as Senior Vice President, Strategic Collaborations & Scientific Affairs.   GlobeNewswire Inc
May 14, 2021
03:03PM EDT  The Promise Of Longevity Science: 3 Small-Cap Companies With Anti-Aging Products   Benzinga
08:11AM EDT  Longeveron Q1 EPS $(0.18)   Benzinga
08:00AM EDT  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update regarding a number of ongoing clinical trials, and also reported its financial results for the first quarter ended March 31, 2021.   GlobeNewswire Inc
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
04:03AM EDT  Earnings Scheduled For May 14, 2021   Benzinga
May 13, 2021
08:10AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use   Benzinga
May 11, 2021
09:00AM EDT  Longeveron to Release First Quarter 2021 Financial Results and   GlobeNewswire Inc
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 5, 2021
09:00AM EDT  Longeveron recently announced positive results from a Phase 1 study of Lomecel-B in Alzheimer's disease, and the completion of two Phase 2 clinical trials evaluating the safety and efficacy of Lomecel-B infusion in Aging Frailty subjects.   GlobeNewswire Inc
Apr 27, 2021
09:00AM EDT  Longeveron Selected to Present at the 2021 World Stem Cell Summit   GlobeNewswire Inc
Apr 22, 2021
08:09AM EDT  The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs   Benzinga
Apr 15, 2021
08:36AM EDT  Longeveron Announces Successful Completion Of Phase I/II Clinical Study Of Lomecel-B Infusion In Aging Frailty Subjects To Improve Immune Response Following Influenza Vaccination   Benzinga
08:30AM EDT  Study intended to evaluate safety, and potential immunomodulatory effect of Lomecel-B on aging-associated decline in antibody response to vaccines in vulnerable population.   GlobeNewswire Inc
Apr 13, 2021
08:36AM EDT  UPDATE: Longeveron Also Says Positive Secondary Efficacy Assessments Support Potential Benefit From Lomecel-B   Benzinga
08:34AM EDT  Longeveron Announces Phase I Study Of Lomecel-B Cell Therapy For Alzheimer's Disease Met Primary Safety Endpoint   Benzinga
08:30AM EDT  Study meets primary safety endpoint; positive secondary efficacy assessments support potential benefit from Lomecel-B   GlobeNewswire Inc
Mar 30, 2021
08:06AM EDT  The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings   Benzinga
07:20AM EDT  Longeveron FY20 Sales $5.63M, Down From $5.64M YoY   Benzinga
07:00AM EDT  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today reported its financial results for the quarter and full year ended December 31, 2020 and provided a business update.   GlobeNewswire Inc
04:04AM EDT  Earnings Scheduled For March 30, 2021   Benzinga
Mar 26, 2021
09:00AM EDT  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced it will host a conference call at 8:30 a.m. Eastern Time on Tuesday, March 30, 2021 to discuss its fiscal 2020 financial results and provide a business update.   GlobeNewswire Inc
07:28AM EDT  The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs   Benzinga
Mar 19, 2021
07:45AM EDT  via InvestorWire Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that Geoff Green, CEO of Longeveron, will be presenting at the Q1 Virtual Investor Summit.   GlobeNewswire Inc
Mar 15, 2021
04:30PM EDT  Longeveron Inc. Announces Partial Exercise of Over-Allotment   GlobeNewswire Inc
Mar 12, 2021
07:36AM EST  The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs   Benzinga
Mar 11, 2021
10:02AM EST  Shares of Longeveron Inc. (LGVN) are rising more than 30% Thursday morning after the clinical-stage biotechnology company announced the expanded access approval by the FDA for the company's drug candidate Lomecel-B in a congenial heart condition.   RTTNews
09:04AM EST  Longeveron's Lomecel-B Approved by FDA for Compassionate Use for the Treatment of Child with Hypoplastic Left Heart Syndrome   Benzinga
09:00AM EST  Longeverons Lomecel-B Approved   GlobeNewswire Inc
Mar 10, 2021
08:37AM EST  Longeveron And University Of Miami Expand Exclusive License Agreement, And Enter Into CRADA To Facilitate Future Collaborations; Financial Details Not Disclosed   Benzinga
08:30AM EST  Longeveron and University of Miami Expand Exclusive License   GlobeNewswire Inc
Mar 5, 2021
08:32AM EST  Longeveron Expands Phase 1 Acute Respiratory Distress Syndrome RECOVER Trial To Include Mild And Severe ARDS   Benzinga
08:30AM EST  Longeveron Expands Enrollment Criteria for its Phase 1 RECOVER   GlobeNewswire Inc
Mar 3, 2021
08:37AM EST  Longeveron Highlights Completion Of Phase 2b Clinical Study Of Lomecel-B Infusion To Treat Aging Frailty; Co Expects Top-Line Data Q3 2021   Benzinga
08:30AM EST  Trial funded in part by a National Institute on AgingSmall Business Innovation Research (SBIR) Grant   GlobeNewswire Inc
Feb 24, 2021
01:44PM EST  Longeveron's Allogeneic Cell Therapy Completes Early-Stage Study In Congenital Heart Defect   Benzinga
09:23AM EST  Longeveron Announces Completion Of Phase 1 Clinical Study Of Lomecel-B Intramyocardial Injection In Hypoplastic Left Heart Syndrome Patients   Benzinga
08:30AM EST  Intramyocardial injection of Lomecel-B well-tolerated, with no major cardiac events, and no serious adverse events related to Lomecel-B reported   GlobeNewswire Inc
Feb 19, 2021
08:30AM EST  CEO of Longeveron Inc. to Present at the Intercontinental Summit   GlobeNewswire Inc
Feb 18, 2021
08:30AM EST  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the appointments of Douglas Losordo, M.D., Erin Borger, and Cathy Ross to the Companys Board of Directors.   GlobeNewswire Inc
08:14AM EST  The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout   Benzinga
Feb 17, 2021
03:50PM EST  Joshua M. Hare Reports In 13D Filing A 42.4% Stake In Longeveron   Benzinga
Feb 12, 2021
10:04AM EST  Longeveron Shares Open For Trade At $10; IPO Priced At $10/Share   Benzinga
Feb 11, 2021
10:27PM EST  Longeveron Inc. Announces Pricing of an Upsized $26.6   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC